Clinical significance of apolipoprotein measurements

  • M. Rosseneu


Apolipoprotein measurements have been applied to the estimation of coronary risk in patients and also to the characterization of various kinds of dyslipidemia, where apolipoprotein profiles are altered in a significant way. The concentration of apolipoprotein B is increased in various types of primary and secondary dyslipidemia including: Type II, III and V primary dyslipidemia, chronic renal failure and Type I, insulin-dependent diabetes. Apo AI concentrations are decreased in Type I, II B and IV dyslipidemia, as well as in liver disease. Apo E is increased in Type III and V dyslipidemia.

The combination of apolipoproteins and lipids quantitation enables a better discrimination between different kinds of dyslipidemia and the choice of an appropriate dietary or drug treatment.


Clinical significance dyslipidemias coronary risks apo AI/Bratio cerebrovascular and cardiovascular disease 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Brown MS, Goldstein JL, Fredrickson DS (1983) Familial type 3 hyperlipoproteinemia (dyslipoproteinemia). In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS (eds) The metabolic basis of inherited disease, 5th edn. McGraw-Hill, New York, 299: 1421–1424Google Scholar
  2. 2.
    De Backer G, Hulstaert F, De Munck K, Rosseneu M, Van Parijs L, Dramaix M (1986) Serum lipids and apoproteins in students whose parents suffered prematurely from a myocardial infarction. Am Heart J 112: 478–484PubMedCrossRefGoogle Scholar
  3. 3.
    De Backer G, Rosseneu M, Deslypere JP (1982) Discriminative value of lipids and apoproteins in coronary heart disease. Atherosclerosis 42: 197–203PubMedCrossRefGoogle Scholar
  4. 4.
    Freedman DS, Srinivasan SR, Shear CL, Franklin FA, Webber LS, Berenson GS (1986) The relation of apolipoproteins AI and B in children to parental myocardial infarction. N Engl J Med 315: 721–726PubMedCrossRefGoogle Scholar
  5. 5.
    Fredrickson DS, Levy RI, Lees RS (1967) Fat transport in lipoproteins: an integrated approach to mechanisms and disorders. N Engl J Med 276: 273–281PubMedCrossRefGoogle Scholar
  6. 6.
    Goldstein JL, Brown MS (1982) The LDL receptor defect in familial hypercholesterolemia. Implication for pathogenesis and therapy. Med Clin North Am 66: 335–362PubMedGoogle Scholar
  7. 7.
    Havel RJ (1982) Familial dysbetalipoproteinemia. New aspects of pathogenesis and diagnosis. Med Clin North Am 66: 441–454PubMedGoogle Scholar
  8. 8.
    Heiss G, Tyroler HA (1983) Are apolipoproteins useful for evaluating ischemic heart disease? A brief overview of the literature. In: Lippel K (ed) Proceedings of the workshop on apolipoprotein quantification. NIH Publication No. 83–1266, Bethesda, pp 7–24Google Scholar
  9. 9.
    Herbert PN, Assmann G, Gotto AM, Fredrickson DS (1983) Familial lipoprotein deficiency: abetalipoproteinemia, hypobetalipoproteinemia, and Tangier disease. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS (eds) The metabolic basis of inherited disease, 5th edn. McGraw-Hill, New York, pp 589–621Google Scholar
  10. 10.
    Leitersdorf E, Gottehrer N, Fainaru M, Friedlander Y, Friedman G, Tzivoni D, Stein G (1986) Analysis of risk factors in 532 survivors of first myocardial infarction hospitalized in Jerusalem. Atherosclerosis 59: 75–93PubMedCrossRefGoogle Scholar
  11. 11.
    Muls E, Blaton V, Rosseneu M, Lesaffre E, Lamberigts G, De Moor P (1982) Serum lipids and apolipoproteins AI, All and B in hyperthyroidism before and after treatment. J Clin Endocrinol Metab 55: 459–464PubMedCrossRefGoogle Scholar
  12. 12.
    Muls E, Rosseneu M, Blaton V, Lesaffre E, Lamberigts G, De Moor P (1984) Serum lipids and apolipoproteins AI, All and B in primary hypothyroidism before and during treatment. Eur J Clin Invest 14: 12–15PubMedCrossRefGoogle Scholar
  13. 13.
    Riesen WF, Mordasini R, Salzmann C, Theler A, Ourtner HP (1980) Apolipoproteins and lipids as discriminators of severity of coronary heart disease. Atherosclerosis 37: 157–162PubMedCrossRefGoogle Scholar
  14. 14.
    Rosseneu M, Bury J (1988) Apolipoprotein assays for the diagnosis of hyperlipidemias. Impact on Prevention of Atherosclerotic Diseases: 143–154Google Scholar
  15. 15.
    Rosseneu M, De Backer G, Caster H, Hulstaert F, Burj J (1987) Distribution and composition of HDL subclasses in students whose parents suffered prematurely from a myocardial infarction in comparison with controls. Atherosclerosis 63: 231–235PubMedCrossRefGoogle Scholar
  16. 16.
    Rosseneu M and Van Biervliet JP (1985) Screening and follow-up of infants with dyslipoproteinemia. In: Widhalm K, Naito H (eds) Detection and treatment of lipid and lipoprotein disorders in childhood. AR Liss, New York, pp 79–86Google Scholar
  17. 17.
    Schaefer EJ (1987) Clinical biochemical and genetic features in familial disorders of high density lipoprotein deficiency. Atherosclerosis 4: 303–315Google Scholar
  18. 18.
    Sedlis SP, Schechtman KB, Ludbrook PA, Sobel BE, Schonfeld G (1986) Plasma apoproteins and the severity of coronary artery disease. Circulation 73: 978–986PubMedCrossRefGoogle Scholar
  19. 19.
    Sniderman AD, Shapiro S, Marpole D, Skinner B, Teng B, Kwiterovich PO (1980) Association of coronary atherosclerosis with hyperapobetalipoproteinemia (increased protein but normal cholesterol levels in human plasma low density lipoproteins). Proc Natl Acad Sci (USA) 77: 604–608CrossRefGoogle Scholar
  20. 20.
    Van Biervliet JP, Vinaimont N, Caster H, Rosseneu M (1982) A screening procedure for dyslipoproteinemia in newborns. Apoprotein quantitation on dried-blood spots. Clin Chim Acta 120: 191–200PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1991

Authors and Affiliations

  • M. Rosseneu
    • 1
  1. 1.Department of Clinical ChemistryA.Z. St-JanBruggeBelgium

Personalised recommendations